KIA
NBIX icon

Knollwood Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Knollwood Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,527
Closed -$916K – 338
2025
Q3 		$916K Sell
6,527
-80
-1% -$10.8K 0.08% 204
2025
Q2 		$830K Hold
6,607
– – 0.08% 209
2025
Q1 		$731K Hold
6,607
– – 0.08% 215
2024
Q4 		$902K Hold
6,607
– – 0.09% 205
2024
Q3 		$761K Hold
6,607
– – 0.08% 227
2024
Q2 		$910K Buy
+6,607
New +$906K 0.1% 202

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Knollwood Investment Advisory's NBIX Position: Q4 2025 in Review

Knollwood Investment Advisory sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 6,527 shares — an estimated $916K sold.

Knollwood Investment Advisory first reported a position in NBIX in Q2 2024 and held it in 6 quarters. The position peaked at $916K in Q3 2025. 731 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Knollwood Investment Advisory reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Knollwood Investment Advisory sold 6,527 Neurocrine Biosciences shares in Q4 2025, an estimated $916K.
  • Knollwood Investment Advisory first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 6 quarters.
  • Knollwood Investment Advisory's Neurocrine Biosciences position peaked at $916K in Q3 2025.
  • 731 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Knollwood Investment Advisory's 13F filing for Q4 2025, filed 13 Feb 2026.